Guatemala vs Republic of Moldova: Average cost of multi drug-resistant tuberculosis treatment
Guatemala
813 constant 2022 US$
in 2024
Republic of Moldova
824 constant 2022 US$
in 2024
Guatemala rank
61st
Republic of Moldova rank
60th
Average cost of multi drug-resistant tuberculosis treatment over time
- Guatemala
- Republic of Moldova
How they compare
Republic of Moldova currently reports 824 constant 2022 US$ against 813 constant 2022 US$ in Guatemala, a difference of 11 constant 2022 US$.
Across all 8 years both countries report, Republic of Moldova has been ahead every year.
Guatemala ranks 61st and Republic of Moldova ranks 60th of 92 countries.
Republic of Moldova has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | Republic of Moldova | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 784.33 constant 2022 US$ | 2,572 constant 2022 US$ | 1,788 constant 2022 US$ | Republic of Moldova |
| 2020s | 781.2 constant 2022 US$ | 1,372 constant 2022 US$ | 591 constant 2022 US$ | Republic of Moldova |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guatemala or Republic of Moldova?
- Republic of Moldova, at 824 constant 2022 US$ against 813 constant 2022 US$ in Guatemala as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guatemala and Republic of Moldova?
- 11 constant 2022 US$, with Republic of Moldova ahead.
- How many years of comparable data are there for Guatemala and Republic of Moldova?
- 8 years are reported by both, from 2017 to 2024.
- How do Guatemala and Republic of Moldova rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guatemala ranks 61st and Republic of Moldova ranks 60th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.